PharmaTher Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Fabio Chianelli

Chief Executive Officer (CEO)

CA$360.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.4yrs
Participación del CEO	17.5%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Fabio Chianelli (46 yo)

4.4yrs

Permanencia

CA$360,000

Compensación

Mr. Fabio Chianelli is the Founder of PharmaTher Holdings Ltd. (formerly known as Newscope Capital Corporation) (formerly known as PharmaTher Inc.). and serves as its Chief Executive Officer since June 03,...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fabio Chianelli	Founder	4.4yrs	CA$360.00k	17.52% $ 2.7m
Beverly Incledon	Independent Director	4.4yrs	sin datos	sin datos
Carlo Sansalone	Independent Director	4.4yrs	sin datos	1.13% $ 175.2k
Christian Scovenna	Independent Director	4.4yrs	sin datos	sin datos

4.4yrs

Permanencia media

48.5yo

Promedio de edad

Junta con experiencia: La junta directiva de PHRR.F se considera experimentada (4.4 años de antigüedad promedio).

PharmaTher Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd., Annual General Meeting, Nov 24, 2023

PharmaTher Holdings Ltd., Annual General Meeting, Nov 25, 2022

Recent updates

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd. Announces Update on FDA New Drug Application for Ketamine

PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine

PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

PharmaTher Holdings Ltd., Annual General Meeting, Nov 24, 2023

PharmaTher Holdings Ltd. Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

PharmaTher Holdings Ltd. Announces Positive Research Results for PharmaPatch with N,N-Dymethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

PharmaTher Holdings Ltd. Initiates Filing of Abbreviated New Drug Application for KETARX to the FDA

New major risk - Share price stability

PharmaTher Holdings Ltd. Announces FDA Approval for KETARX

PharmaTher Holdings Ltd. Submits FDA Meeting Package to Discuss 505(B)(2) Pathway for New Drug Application of Ketarx (Ketamine) On-Body Pump System

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX (Ketamine) in Parkinson's Disease

PharmaTher Holdings Ltd. Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

Pharmather Holdings Ltd. Announces A Poster Presentation of the Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’S Disease

PharmaTher Holdings Ltd. to Present Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease At the MDS International Congress of Parkinson's Disease and Movement Disorders

PharmaTher Holdings Ltd., Annual General Meeting, Nov 25, 2022

PharmaTher Holdings Ltd. Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketarx Ketamine Patch

PharmaTher Holdings Ltd Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders

PharmaTher Holdings Ltd. Announces Positive Results from Study for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Announces Positive Results from Study of Ketabet™ for Depression

PharmaTher Holdings Ltd. Announces FDA Approval of Investigational New Drug Application for Ketamine to Treat ALS

PharmaTher Holdings Ltd. Announces Publication of Research Data for Ketabet™

PharmaTher Holdings Ltd Provides Product Pipeline Update and Expected Milestones for 2022

PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

PharmaTher Holdings Ltd. announced that it expects to receive CAD 10 million in funding

Pharmather Holdings Ltd. Provides Product Pipeline Update

PharmaTher Holdings Ltd. Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Holdings Ltd. Files FDA Pre-IND Meeting Request and Briefing Package for KETABET™ to Treat Depression

Pharmather Holdings Ltd. Provides Research and Development Update and Milestones for 2021

Pharmather Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

PharmaTher Announces FDA Approval of Ketamine IND in the Treatment of Parkinson’s Disease

PharmaTher Holdings Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

PharmaTher Inc. Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

Newscope Capital Corporation Announces Successful Completion of a Type B Pre-Investigational New Drug

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad